Mastocytosis Drug Market Report 2026

The mastocytosis drug market size has grown strongly in recent years. It will grow from $1.17 billion in 2025 to $1.28 billion in 2026 at a compound annual growth rate (CAGR) of 9.7%. The growth in the historic period can be attributed to rare disease recognition, antihistamine-based symptom control, hospital-led diagnosis, limited therapeutic options, specialist-driven care.

The mastocytosis drug market size is expected to see strong growth in the next few years. It will grow to $1.84 billion in 2030 at a compound annual growth rate (CAGR) of 9.4%. The growth in the forecast period can be attributed to targeted drug approvals, orphan drug incentives, genetic mutation profiling, expansion of specialty clinics, improved diagnostic capabilities. Major trends in the forecast period include growing focus on rare mast cell disorders, increased use of targeted therapies, expansion of symptom management drugs, rising awareness of systemic mastocytosis, development of personalized treatment protocols.

The rising investment in rare diseases is anticipated to drive the growth of the mastocytosis drug market in the coming years. Rare diseases are defined as medical conditions that affect a limited portion of the population, generally fewer than 200,000 individuals in the United States or fewer than 1 in 2,000 people in Europe. The growth in investment for rare diseases is mainly supported by increasing regulatory incentives, including orphan drug designations, prolonged market exclusivity, and tax credits, which lower development risks and improve profitability for pharmaceutical manufacturers. Mastocytosis drugs provide targeted therapies that not only help manage mastocytosis symptoms but also support broader therapeutic progress for other rare diseases that share similar immune and cellular mechanisms. For instance, in April 2024, according to Global Genes, a US-based nonprofit organization, during the first quarter of 2024, companies developing rare disease therapies raised $7.1 billion through public equity and debt financing, reflecting a 307% increase compared to the $1.8 billion raised in the same period of 2023. Therefore, the rising investment in rare diseases is fueling the growth of the mastocytosis drug market.

Leading companies operating in the mastocytosis drug market are concentrating on the development of innovative products such as tyrosine kinase inhibitors to enhance treatment effectiveness and deliver targeted therapies for patients with advanced mast cell disorders. A tyrosine kinase inhibitor is a medication that suppresses enzymes responsible for abnormal cell growth, and in mastocytosis, it works by limiting excessive mast cell proliferation and alleviating symptoms such as skin rashes and inflammation. For example, in May 2023, Blueprint Medicines Corporation, a US-based biotechnology firm, obtained approval from the U.S. Food and Drug Administration for Ayvakit (avapritinib) for treating adults with indolent systemic mastocytosis (ISM). This approval represents a notable advancement in addressing ISM, a rare chronic condition marked by excessive mast cell production. Ayvakit functions as a selective inhibitor of the KIT D816V mutation, which is commonly found in ISM patients, providing a targeted therapeutic option to manage symptoms and disease progression.

In May 2024, Incyte Corporation, a US-based biopharmaceutical company, acquired Escient Pharmaceuticals for approximately $750 million. Through this acquisition, Incyte seeks to enhance its Inflammation and Autoimmunity (IAI) pipeline by incorporating Escient Pharmaceuticals’ first-in-class oral MRGPR antagonists, thereby strengthening its ability to develop novel therapies for severe immune and neuro-immune conditions. Escient Pharmaceuticals is a US-based clinical-stage biotechnology company focused on the development of EP262, a first-in-class oral MRGPRX2 antagonist aimed at treating mast cell-mediated diseases.

Major companies operating in the mastocytosis drug market are Pfizer Inc., Johnson & Johnson, Bayer AG, Sanofi S.A., Novartis AG, GSK plc, Teva Pharmaceutical Industries Limited, Alcon Inc., Bausch Health Companies Inc., Genentech Inc., Lupin Limited, Blueprint Medicines Corporation, Don Valley Pharma (Pvt.) Ltd., Vivan Life Sciences Private Limited, AB Science S.A., Medoz Pharmaceutical Private Limited, Zumax Biocare Private Limited, Hi-Cure Biotech Private Limited, Zenomed Healthcare Private Limited, Biosynth AG.

North America was the largest region in the mastocytosis drug market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the mastocytosis drug market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the mastocytosis drug market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs have impacted the mastocytosis drug market by raising costs for antihistamines, corticosteroids, mast cell stabilizers, and pharmaceutical excipients. Systemic mastocytosis treatments are most affected, especially in North America and Europe where imported specialty drugs and raw materials dominate. Hospitals and specialty clinics face higher therapy costs. However, tariffs are encouraging domestic formulation of rare-disease drugs and strengthening local pharmaceutical supply chains.

The mastocytosis drug market research report is one of a series of new reports that provides mastocytosis drug market statistics, including mastocytosis drug industry global market size, regional shares, competitors with a mastocytosis drug market share, detailed mastocytosis drug market segments, market trends and opportunities, and any further data you may need to thrive in the mastocytosis drug industry. This mastocytosis drug market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Mastocytosis drugs are medications designed to treat mastocytosis, a rare disorder marked by the abnormal buildup of mast cells in the skin, bone marrow, and internal organs. These therapies focus on controlling symptoms, lowering mast cell activity, or managing severe and aggressive forms of the condition.

The primary categories of mastocytosis drugs include antihistamines, corticosteroids, and mast cell stabilizers. Antihistamines are commonly used as first-line treatments to alleviate mastocytosis symptoms by preventing histamine from attaching to its receptors during allergic responses. These medications are prescribed for conditions such as systemic mastocytosis, cutaneous mastocytosis, and mast cell activation syndrome. They can be administered via oral, intravenous, or subcutaneous routes. Distribution channels comprise hospital pharmacies, online pharmacies, retailers, and other sources. The key end users include hospitals, homecare environments, specialty clinics, and other healthcare providers.

The mastocytosis drug market also includes sales of antihistamines, leukotriene receptor antagonists, corticosteroids, tyrosine kinase inhibitors (TKIs), and epinephrine. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.